Effect of Vitamin C Administration on Intraoperative Bleeding in Patients Undergoing Sinusoscopy

NCT07866274 | Not Yet Recruiting Phase 2

• 1 other identifier: Vitamin C for Sinusoscopy
• Study Type: interventional
• Target: 78
• Locations: 0 countries
• Sites: N/A

Brief Summary

Functional endoscopic sinus surgery (FESS), or sinusoscopy, is a standard surgical procedure used to treat chronic rhinosinusitis and other conditions of the nasal sinuses. However, bleeding during surgery is a frequent challenge that can obstruct the surgeon's view, lengthen operative time, and increase the risk of complications. Vitamin C (ascorbic acid) supports collagen synthesis, capillary wall strength, and blood vessel integrity, which may help minimize mucosal bleeding during surgical procedures. The purpose of this randomized clinical trial is to evaluate whether administering preoperative Vitamin C reduces intraoperative bleeding, enhances surgical field visibility, and shortens operative duration in adult patients undergoing elective sinusoscopy. Participants will be randomly assigned to one of two groups:

• Vitamin C Group: Receives a standardized 500 mg dose of Vitamin C before surgery.
• Control Group: Receives standard perioperative care/placebo before surgery. Total blood loss will be recorded during surgery, surgical field clarity will be evaluated every 15 minutes using the Boezaart scale, and participants will be monitored for postoperative bleeding and potential side effects for up to 48 hours.

Conditions

Chronic Rhinosinusitis; Intraoperative Bleeding; Blood Loss, Surgical

Keywords

Vitamin C; Ascorbic Acid; Functional Endoscopic Sinus Surgery; FESS; Sinusoscopy; Surgical Field Visibility; Boezaart Scale; Epistaxis

Outcome Measures

Primary Outcomes (1)

• Total Intraoperative Blood Loss

  Total intraoperative blood loss measured in milliliters (mL). Calculated as the total fluid collected in the suction canisters minus the volume of surgical irrigation fluid used, added to the volume calculated from blood-soaked gauzes (determined gravimetrically: wet gauze weight minus dry gauze weight, where 1 g = 1 mL).

  Through completion of surgery, up to 2 hours

Study Arms (2)

Vitamin C Group

EXPERIMENTAL

Patients scheduled for elective functional endoscopic sinus surgery (FESS) receiving a standardized dose of 500 mg Vitamin C (ascorbic acid) preoperatively in addition to standard general anesthesia and monitoring.

Drug: Ascorbic acid

Control Group

PLACEBO COMPARATOR

Patients scheduled for elective functional endoscopic sinus surgery (FESS) receiving matching placebo or standard perioperative care preoperatively in addition to standard general anesthesia and monitoring.

Other: Placebo

Interventions

Ascorbic acid DRUG

Administration of a standardized dose of 500 mg Vitamin C (ascorbic acid) preoperatively prior to functional endoscopic sinus surgery (FESS).

Also known as: Vitamin C

Vitamin C Group

Placebo OTHER

Administration of matching placebo or standard perioperative care preoperatively prior to functional endoscopic sinus surgery (FESS).

Control Group

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients scheduled for elective functional endoscopic sinus surgery (FESS / sinusoscopy)
• Age between 18 and 65 years
• American Society of Anesthesiologists (ASA) physical status I or II

You may not qualify if:

• Pre-existing bleeding disorders, coagulopathy, or concurrent anticoagulant/antiplatelet therapy
• History of renal stones (nephrolithiasis) or severe renal impairment
• Pregnant or lactating females
• Current smokers

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Blood Loss, Surgical; Epistaxis

Interventions

Ascorbic Acid

Condition Hierarchy (Ancestors)

Hemorrhage; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Intraoperative Complications; Nose Diseases; Respiratory Tract Diseases; Otorhinolaryngologic Diseases; Signs and Symptoms, Respiratory; Signs and Symptoms

Intervention Hierarchy (Ancestors)

Sugar Acids; Acids, Acyclic; Carboxylic Acids; Organic Chemicals; Hydroxy Acids; Carbohydrates

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident

Study Record Dates

• First Submitted: October 4, 2026
• First Posted: October 8, 2026
• Study Start (Estimated): November 1, 2026
• Primary Completion (Estimated): November 1, 2027
• Study Completion (Estimated): December 1, 2027
• Last Updated: October 8, 2026

Record last verified: 2026-10